Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action! Authors' reply-Reference-Cited by-同舟云学术

Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action! Authors' reply

Published:2023-04-24 Issue:10 Volume:57 Page:1172-1173
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Zhang Xinrong¹²,Wong Grace Lai‐Hung¹²^ORCID,Wong Vincent Wai‐Sun¹²^ORCID,Yip Terry Cheuk‐Fung¹²^ORCID

Affiliation:

1. Medical Data Analytics Centre, Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong China

2. State Key Laboratory of Digestive Disease Institute of Digestive Disease, The Chinese University of Hong Kong Hong Kong China

Abstract

LINKED CONTENTThis article is linked to Zhang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17428 and https://doi.org/10.1111/apt.17467

Funder

Health and Medical Research Fund

Chinese University of Hong Kong

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17474

Reference8 articles.

1. Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study

2. Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease—time for action!

3. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis

4. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease

5. Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease